All In Biotech

Drug Trial Radar · NCT06230588

A Clinical Trial of TQH3906 Capsules in Healthy Volunteers

A Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of TQH3906 Capsules in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Jul 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

96

Actual

Start

Feb 2, 2024

Primary completion

Apr 27, 2025

Study completion Apr 27, 2025

Sponsor

Sponsor type
Industry
First posted
Jan 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study was divided into three parts: single and multiple dosing and food effect study, which were designed to evaluate the safety and tolerability of TQH3906 capsules administered in single or multiple dose escalation in healthy adult subjects.

Conditions

  • Psoriasis

Interventions

  • TQH3906 capsuleDrug

    TQH3906 is a kinase inhibitor.

  • TQH3906 placeboDrug

    Placebo Comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AE)Time frame: Up to 18 days
  2. Serious Adverse Events (SAE)Time frame: Up to 18 days
  3. Treatment-emergent adverse events (TEAEs)Time frame: Up to 18 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.